Spasticity Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, by DelveInsight | Lundbeck, Revance Therapeutics, Ipsen, Saol Therapeutics, Huons, Medy-Tox, Sun Pharma

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spasticity pipeline constitutes 20+ key companies continuously working towards developing 20+ Spasticity treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Spasticity Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spasticity Market.

The Spasticity Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Spasticity Pipeline Report: https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Spasticity treatment therapies with a considerable amount of success over the years.
• Spasticity companies working in the treatment market are Lundbeck, Revance Therapeutics, Ipsen, Saol Therapeutics, Huons, Medy-Tox, Sun Pharma, Acorda Therapeutics, XenoPort, Inc., and others, are developing therapies for the Spasticity treatment
• Emerging Spasticity therapies in the different phases of clinical trials are- Lu AG06466, DAXXIFY, IPN10200, SIL 1002, HU-014, Botulinum toxin type A, SPARC1103, Tizanidine, XP19986, and others are expected to have a significant impact on the Spasticity market in the coming years.
• In July 2021, In order to assess the safety and effectiveness of HU-014 Inj in the treatment of post-stroke upper limb spasticity, Huons started a multi-center, Phase III clinical research. Five upper limb muscles received injections of HU-014 Inj (a total of 360 U/, IM).
• In April 2021, The acquisition of an exclusive licence to register, sell, and commercialise botulinum toxin in the United States and Canada by Aquavit Holdings LLC was announced. Through a recent clinical research, Aquavit demonstrated the efficacy and safety of its proprietary delivery technology and associated intellectual property for botulinum toxin.
• Revance Therapeutics is now in Phase II of the clinical development of RT-002, which is being used to treat upper limb muscle spasticity. GlobalData claims that there is insufficient historical data for Phase II medicines for Upper Limb Muscle Spasticity to create an indication benchmark PTSR.

Spasticity Overview
Spasticity is a disorder marked by an unnatural rise in muscular tone or stiffness, which may impair speech or movement and be accompanied by discomfort or pain. Damage to the nerve pathways in the brain or spinal cord that regulate muscle action is the usual cause of spasticity.

Get a Free Sample PDF Report to know more about Spasticity Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Spasticity Drugs Under Different Phases of Clinical Development Include:
• Lu AG06466: Lundbeck
• DAXXIFY: Revance Therapeutics
• IPN10200: Ipsen
• SIL 1002: Saol Therapeutics
• HU-014: Huons
• Botulinum toxin type A: Medy-Tox
• SPARC1103: Sun Pharma
• Tizanidine: Acorda Therapeutics
• XP19986: XenoPort, Inc.
• Myobloc: Supernus Pharmaceuticals

Spasticity Route of Administration
Spasticity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Spasticity Molecule Type
Spasticity Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Spasticity Pipeline Therapeutics Assessment
• Spasticity Assessment by Product Type
• Spasticity By Stage and Product Type
• Spasticity Assessment by Route of Administration
• Spasticity By Stage and Route of Administration
• Spasticity Assessment by Molecule Type
• Spasticity by Stage and Molecule Type
DelveInsight's Spasticity Report covers around 20+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Spasticity product details are provided in the report. Download the Spasticity pipeline report to learn more about the emerging Spasticity therapies at:
https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Spasticity Therapeutics Market include:
Key companies developing therapies for Spasticity are - Allergan Plc, Alembic Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Covis Pharma BV, Dr. Reddys Laboratories Ltd., Endo International Plc, F. Hoffmann La Roche Ltd., Hikma Pharmaceuticals Plc, Ipsen Pharma, Jazz Pharmaceuticals Plc, Mayne Pharma Group Ltd., Merz Pharma GmbH and Co. KGaA, Pfizer Inc., Piramal Enterprises Ltd., Sun Pharmaceutical Industries Ltd., Unichem Laboratories Ltd., US WorldMeds, Cadila Healthcare Ltd., Medtronic Plc, JPN Pharma Pvt. Ltd., and others.

Spasticity Pipeline Analysis:
The Spasticity pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Spasticity with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spasticity Treatment.
• Spasticity key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Spasticity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spasticity market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Spasticity drugs and therapies-
https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Spasticity Pipeline Market Drivers
• Increasing prevalence of stroke, multiple sclerosis, and brain injury drive the market, increasing R&D for developing effective therapies are some of the important factors that are fueling the Spasticity Market.

Spasticity Pipeline Market Barriers
• However, high cost of the treatment, lack of disease awareness in emerging economies and other factors are creating obstacles in the Spasticity Market growth.

Scope of Spasticity Pipeline Drug Insight
• Coverage: Global
• Key Spasticity Companies: Lundbeck, Revance Therapeutics, Ipsen, Saol Therapeutics, Huons, Medy-Tox, Sun Pharma, Acorda Therapeutics, XenoPort, Inc., and others
• Key Spasticity Therapies: Lu AG06466, DAXXIFY, IPN10200, SIL 1002, HU-014, Botulinum toxin type A, SPARC1103, Tizanidine, XP19986, and others
• Spasticity Therapeutic Assessment: Spasticity current marketed and Spasticity emerging therapies
• Spasticity Market Dynamics: Spasticity market drivers and Spasticity market barriers

Request for Sample PDF Report for Spasticity Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/spasticity-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Spasticity Report Introduction
2. Spasticity Executive Summary
3. Spasticity Overview
4. Spasticity- Analytical Perspective In-depth Commercial Assessment
5. Spasticity Pipeline Therapeutics
6. Spasticity Late Stage Products (Phase II/III)
7. Spasticity Mid Stage Products (Phase II)
8. Spasticity Early Stage Products (Phase I)
9. Spasticity Preclinical Stage Products
10. Spasticity Therapeutics Assessment
11. Spasticity Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Spasticity Key Companies
14. Spasticity Key Products
15. Spasticity Unmet Needs
16 . Spasticity Market Drivers and Barriers
17. Spasticity Future Perspectives and Conclusion
18. Spasticity Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Spasticity Market https://www.delveinsight.com/report-store/spasticity-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Spasticity-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Spasticity Epidemiology https://www.delveinsight.com/report-store/spasticity-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Spasticity Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.